eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
eXoZymes, Inc.NASDAQ: EXOZ
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $74.15K rose 5.2% year over year, behind the +6.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +24.9% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.2% toward the trailing-twelve-month pace of +6.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 287.96K USD
- Year-over-year change
- +7.7%
- 4-year CAGR
- +48.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287.96K | +7.7% |
| FY2024 | 2024-12-31 | 267.38K | +35.8% |
| FY2023 | 2023-12-31 | 196.94K | +33.3% |
| FY2022 | 2022-12-31 | 147.75K | +148.7% |
| FY2021 | 2021-12-31 | 59.41K | — |
Depreciation & Amortization vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.0% is the 2nd highest of 7, against a peer median of -76.4%.
- Over three fiscal years its annual growth of +24.9% compares with a peer median of -26.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $308K USD | -77.1% | -35.0% | 4.1% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $291.61K USD | +6.0% | +24.9% | — |
| LTM Mar 2026 | $291K USD | -90.7% | -55.3% | — | |
| LTM Mar 2026 | $251K USD | -0.8% | -1.0% | — | |
| FY2025 | $234K USD | +88.7% | +55.1% | — | |
| LTM Mar 2026 | CA$75.25K CAD | -79.8% | -31.7% | — | |
| LTM Mar 2026 | $876 USD | -75.7% | -21.0% | — | |
| Peer median (excluding EXOZ) | — | -76.4% | -26.4% | 4.1% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 59.41K | 147.75K | 0 | 267.38K | 0 |
| Gross Profit | (59.41K) | (147.75K) | 0 | (267.38K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 454.45K | 348.08K | 527.48K | 1.87M | 3.71M |
| Selling, General & Admin | 778.99K | 836.83K | 1.34M | 3.8M | 5.91M |
| Operating Expenses | 1.23M | 1.18M | 1.8M | 5.66M | 9.72M |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | 287.96K |
| EBITDA | (1.15M) | (1.18M) | (1.8M) | (5.59M) | (8.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.29M) | (1.33M) | (1.8M) | (5.93M) | (9.72M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 98 | 100 | 77.61K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 83.74K | 98 | (199.9K) | 70.77K | 452.53K |
| Income Before Tax | (1.21M) | (1.33M) | (2M) | (5.86M) | (9.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 63.56K | 42.27K | 0 | (105.21K) |
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| EPS (Diluted) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| Weighted Avg Shares | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
| Weighted Avg Shares (Diluted) | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.